PubMed
Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I
Ballard FJ, Wallace JC, Francis GL, et al. Int J Biochem Cell Biol. 1996
Compare
IGF-1 DES vs IGF-1 LR3
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
IGF-1 DES
2337 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 51% · Mixed 32% · Unfavorable overall 17%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Skin appearance
48
Appetite control
39
Energy
127
Mood
93
Focus
112
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
144
GI discomfort
118
Dizziness
92
Fatigue
89
Nausea
111
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.05–2 mg
0.05–0.1 mg
7
0.1–0.2 mg
15
0.2–0.4 mg
18
0.4–0.6 mg
14
0.6–1 mg
8
1–2 mg
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
timing21stacking19side effects17igf-1 des20
How repeat users are trending
Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 23 days · Based on 514 repeat reporters
IGF-1 LR3
30 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
171
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Water retention
5
Self-reported dose per injection
Median bucket: 50–100 mcg · Most common: 10–25 mcg
Reports span 0–200 mcg
0–10
1
10–25
60
25–50
1
50–100
53
100–200
56
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 96% said they felt similar to their last entry, 4% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 153 days · Based on 28 repeat reporters
Sources (10)
Published sources linked on the IGF-1 DES and IGF-1 LR3 wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice
Gillespie C, Read LC, Bagley CJ, et al. J Endocrinol. 1990
- Wiki study page →Source
PubMed
In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness
Walton PE, Dunshea FR, Ballard FJ. Prog Growth Factor Res. 1995
- Wiki study page →Source
PubMed
IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys
Tomas FM, Walton PE, Dunshea FR, et al. J Endocrinol. 1997
- Wiki study page →Source
PubMed
Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats
Read LC, Tomas FM, Howarth GS, et al. J Endocrinol. 1992
- Wiki study page →Source
ClinicalTrials.gov
des(1-3)IGF-1 / IGF-1 DES studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Insulin-like growth factor-I and its binding proteins in sport and exercise medicine
Baxter RC. Endocr Rev. 2011
- Wiki study page →Source
ClinicalTrials.gov
IGF-1 LR3 studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice
Engel MG, Narayan S, Cui MH, et al. Journal of Alzheimer's disease : JAD. 2025
- Wiki study page →Source
PubMed
Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration
Yavuz E, Sağır MS, Ercan A, et al. International journal of biological macromolecules. 2025